Urinary TGF-β1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy

Diabetes Research and Clinical Practice

Volumn 72, Issue 3, 2006, Pages 258-264

  Bertoluci, Marcello Casaccia ^a   Uebel, Deise ^a   Schmidt, Alexandre ^a   Thomazelli, Fulvio Clemo Santos ^a   Oliveira, Fábio Ramos ^a   Schmid, Helena ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Diabetic nephropathy; Hypertension; TGF

Indexed keywords

AMLODIPINE; ATENOLOL; CAPTOPRIL; ENALAPRIL; PROPRANOLOL DERIVATIVE; RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA1; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HYDROCHLOROTHIAZIDE; POTASSIUM; PROPRANOLOL;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET THERAPY; DRUG COMBINATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; MIDDLE AGED; URINE;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD GLUCOSE; BLOOD PRESSURE; CAPTOPRIL; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; POTASSIUM; PROPRANOLOL; RAMIPRIL; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33646717947     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.10.027     Document Type: Article

References (25)

1. Border W.A., Yamamoto T., and Noble N.A. Transforming growth factor beta in diabetic nephropathy. Diab. Metab. Rev. 12 (1996) 309-339
2. Bertoluci M.C., Schmid H., Lachat J.J., and Coimbra T.M. Transforming growth factor-beta in the development of rat diabetic nephropathy. Nephron 74 (1996) 189-196
3. Sharma K., Jin Y., Guo J., and Ziyadeh F.N. Neutralization by TGF-β antibody attenuates kidney hypertrophy and the enhanced extra-cellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45 (1996) 522-530
4. Sharma K., Ziyadeh F.N., Alzahabi B., McGowan T.A., Kapoor S., Kurnick B.R., et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46 (1997) 854-859
5. Bertoluci M.C., Schaan B.D., Coimbra T.M., and Schmid H. Increased urinary TGF-β1 in type 2 diabetic patients with diabetic nephropathy. Diabetes 47 Suppl. 1 (1998) 0504
6. Bertoluci M.C., Machado M.P., Lima K.M., Thome F., Barros E., Veronese F., et al. Increased urinary TGF-β1 in diabetic nephropathy in comparison to non-diabetic nephropathies. Diabetes 49 Suppl. 1 (2000) 229-OR
7. Ellis D., Forrest K.Y., Erbey J., and Orchard T.J. Urinary measurement of transforming growth factor beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin.Chem. 44 (1998) 950-956
8. Rivarola E.W.R., Moyses-Neto M., Dantas M., da Silva C.G., Volpini R., and Coimbra T.M. Transforming growth factor beta activity in urine of patients with type 2 diabetes and diabetic nephropathy. Braz. J. Med. Biol. Res. 32 (1999) 1525-1528
9. Sato H., Iwano M., Akai Y., Kurioka H., Kubo A., Yamaguchi T., et al. Increased excretion of urinary transforming growth factor beta-1 in patients with diabetic nephropathy. Am. J. Nephrol. 18 (1988) 490-494
10. Remuzzi G., Schieppati A., and Ruggenenti P. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 346 (2002) 1145-1151
11. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
12. Ziyadeh F.N., Sharma K., Ericksen M., and Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J. Clin. Invest. 74 (1994) 536-542
13. Schaan B.D., Lachchini S., Bertoluci M.C., Irigoyen M.C., Machado U.F., and Schmid H. Increased Renal GLUT1 abundance and Urinary TGF-β1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Horm. Metab. Res. 33 (2001) 6664-6669
14. Zatz R., Dunn B.R., Meyer T.W., Anderson S., Rennke H.G., and Brenner B.M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest. 77 (1986) 1925-1930
15. Krolewski A.S., Canessa M., Warram J.H., Laffel L.M.B., Christlieb R., Knowler W.C., et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N. Engl. J. Med. 318 (1998) 140-150
16. Canani L.H., Gerchman F., and Gross J.L. Familial clustering of diabetic nephropathy in brazilian type 2 diabetic patients. Diabetes 48 (1999) 909-913
17. Riser B., Ladson-Wofford S., Sharba A., Cortes P., Drake K., Guerin C.J., et al. TGF-β receptor expression and binding in rat mesangial cells: modulation by glucose and cyclic mechanical strain. Kidney Int. 56 (1999) 428-439
18. Riser B.L., Cortes P., Heilig C., Grondin J., Ladson-Wofford S., Patterson D., et al. Cyclic stretching force selectively up-regulates transforming growth factor-β isoforms in cultured rat mesangial cells. Am. J. Pathol. 148 (1996) 1915-1923
19. Wolf G. Link between angiotensin II and TGF-β in the kidney. Miner. Electrolyte Metab. 24 (1998) 174-180
20. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (2001) 861-869
21. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Raz I: renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345 (2001) 851-860
22. Houlihan C.A., Akdeniz A., Tsalamandris C., Cooper M.A., Jerums G., and Gilbert R.E. Urinary transforming growth factor β excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate. Diab. Care 25 (2002) 1072-1077
23. Iwano M., Kubo A., Nishino T., Sato H., Nishioka H., Akai Y., et al. Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int. 49 (1996) 1120-1126
24. Sharma K., Eltayeb B.O., McGowan T.A., Dunn S.R., Alzahabi B., Rohde R., et al. Captopril-induced reduction of serum levels of transforming growth factor-beta 1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am. J. Kidney Dis. 34 (1999) 818-823
25. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., and Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42 (1993) 450-456